Glaukos Corporation Third-Quarter Results

Glaukos Corporation (NYSE: GKOS) has reported a substantial increase in its third-quarter net sales, showcasing a 24% year-over-year rise to $96.7 million. This growth was chiefly fueled by the U.S. glaucoma franchise, which posted a 35% increase in sales. In light of these results, the company has revised its sales guidance for full-year 2024 to a range between $3.77 million and $3.79 million.

Key Takeaways

• Glaukos experienced a 24% year-over-year increase in Q3 net sales to $96.7 million.
• U.S. glaucoma franchise sales primarily from iDose TR and iStent, grew by 35%.
• Full-year 2024 sales guidance has been raised to $3.77 million – $3.79 million.
• The launch of iDose TR was deemed successful; a permanent J-code is effective from July 1, 2024.
• Positive feedback from Epioxa's second Phase 3 study; NDA submission is anticipated by the end of 2024.
• Plans to convert $57.5 million in convertible Senior Notes to common stock before December 16, 2024.
• Anticipation of top-line growth acceleration in 2025, driven by iDose.

Company Outlook

• Glaukos remains optimistic about growth prospects, buoyed by its glaucoma and corneal health franchises.
• The company aims for cash flow breakeven and future profitable quarters, correlating to the iDose launch momentum.
• Gross margins for 2024 are projected between 82% and 83%, with expected improvements by late 2025.

Challenges and Opportunities

Bearish Highlights

• Ongoing reimbursement challenges persist with certain Medicare Administrative Contractors (MACs).
• Manufacturing inefficiencies related to the iDose launch have influenced gross margin projections.

Bullish Highlights

• Strong growth in the U.S. glaucoma franchise, with iDose TR sales doubling from the previous quarter.
• Licensing agreements with Ripple Therapeutics aim to expand into intravitreal implants.
• Favorable FDA feedback regarding Epioxa's clinical data, with NDA submission on track.

Misses

• No specific misses reported in the summary.

Q&A Highlights

• Discussion on expanding market access and reimbursement for iDose in 2025.
• The company plans to enter clinical trials for the next-generation iDose TREX by year-end 2023.
• Advancements in Phase I clinical studies of Axitinib for age-related macular degeneration, with data preview expected by late 2025.

Glaukos Corporation's strong Q3 performance, combined with strategic initiatives, underscores its commitment to enhance treatment options for glaucoma and corneal health. The focus on market access and reimbursement, along with a promising product pipeline, positions Glaukos for sustained growth.

InvestingPro Insights

According to InvestingPro, Glaukos's revenue growth for the past twelve months is 18.7%, with a quarter-on-quarter growth of 23.86% for Q3 2024.

The company boasts a market capitalization of $7.11 billion, but is currently not profitable, showcasing an adjusted operating income of -$116.09 million for the last twelve months. Despite the upbeat sales growth, analysts do not foresee profitability this year.

Investors are optimistic about Glaukos's future as the stock reflects a strong return of 15.63% over the last three months, trading near its 52-week high. Positive sentiment is likely driven by iDose TR's successful launch and Glaukos's burgeoning product pipeline.

Conclusion

Glaukos Corporation's solid third-quarter results and strategic plans indicate its strong commitment to advancing treatment options. The financial strategy prioritizes cash flow breakeven, showcasing a prudent approach to resource management while ambitious growth objectives are pursued.